The decision by Johnson & Johnson to split Kenvue was presented as both sensible and progressive. The well-known brands that were formerly grouped together under the corporate giant—Tylenol, Band-Aid, Listerine, and Neutrogena—were formally housed under a new name by August 2023. It was a calculated decision that left Kenvue to continue the tradition of everyday necessities while Johnson & Johnson concentrated on pharmaceuticals and medical devices. The answer to the frequently asked question, “Is Kenvue owned by Johnson & Johnson?” is now very clear: no.
The spin-off’s reasoning was especially creative. Johnson & Johnson profited from the halo effect of customer trust for many years. Without hesitation, parents reached for Johnson’s Baby Shampoo, and Band-Aids came to represent safety. However, the data showed a different picture. In 2021, pharmaceuticals and devices brought in almost $77 billion, while consumer health brought in $15 billion. Johnson & Johnson was able to focus on high-margin scientific innovation by utilizing the spin-off model, while Kenvue was able to fortify its iconic brand.
The Wall Street debut was a remarkable success in attracting attention for Kenvue. With a valuation close to $41 billion, its initial public offering (IPO) raised $3.8 billion, one of the largest since Rivian. Investors were reassured by the action that stable brands can be established when allowed autonomy. However, difficulties soon emerged. A phenylephrine disclosure lawsuit brought to light weaknesses that independence invariably reveals. The scrutiny was eerily reminiscent of the harsher criticism that celebrities encounter when they leave the shield of a prominent label.
Table: Kenvue Company Profile
| Category | Details |
|---|---|
| Company Name | Kenvue Inc. |
| Founded | February 23, 2022 |
| Former Parent | Johnson & Johnson (Consumer Health Division) |
| Headquarters | Summit, New Jersey, U.S. |
| Industry | Consumer Health Products |
| Key People | Kirk Perry (CEO, 2025– ), Larry Merlo (Chairman), Thibaut Mongon (former CEO) |
| Brands | Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno, Johnson’s Baby, Zyrtec, Visine |
| IPO | May 4, 2023 – Raised $3.8 billion |
| Revenue (2024) | $15.5 billion |
| Employees | ~22,000 |
| Status | Independent Company (J&J fully divested in 2023–24) |
| Reference | Kenvue Wikipedia |
Kenvue has also been caught in the crossfire of politics in recent days. Despite numerous scientific denials, public figures such as former President Trump and Robert F. Kennedy Jr. made accusations regarding Tylenol’s safety and connected it to autism. Maintaining customer trust while navigating false information has proven especially difficult for Kenvue. The situation seems remarkably similar to the ongoing balancing act between legacy and reinvention that public figures like Meghan Markle and Harry Styles must perform when managing narratives.
Through restructuring and strategic alliances, Johnson & Johnson successfully exited the market. The last divestment was a $3.75 billion debt-for-equity exchange with Goldman Sachs and J.P. Morgan in 2024. Johnson & Johnson had sold off its 9.5% stake by that point. In addition to being legal, Kenvue’s independence became symbolic—a tale of a child emerging from a parent’s shadow.
But Kenvue isn’t just getting by. Its brands continue to be incredibly dependable fixtures in American and international homes. There are still Band-Aid boxes in kitchens, Tylenol on medicine cabinets, and Neutrogena products on bathroom counters. The way the business presents its future makes a difference. By emphasizing innovation in sustainability, wellness, and product design, Kenvue hopes to play a significant role in influencing the health habits of its customers.
Large corporations from a variety of industries have realized the importance of focus during the last ten years. General Electric divided into more manageable companies. The consumer health division of Pfizer was relocated to Haleon. In contrast, Johnson & Johnson’s establishment of Kenvue, which was motivated by the idea that specialization increases a company’s efficiency and financial strength, is remarkably similar. These changes are more important to consumers in terms of practical trust than in terms of corporate terms. When someone purchases Listerine, they want to know if it works, not if it’s J&J or Kenvue.
A complex picture is painted by financial data. Revenue hit $15.5 billion in 2024, but restructuring and legal expenses caused operating income and net profits to decline. Although there is some short-term volatility, analysts point out that consumer goods’ long-term stability is remarkably stable. Making sure that brands change is the current challenge. Kenvue needs to preserve Neutrogena and Aveeno’s legacy while keeping them current, much like Taylor Swift changes who she is throughout her albums.
The goal of the move for Johnson & Johnson was to increase focus rather than to shrink. Thanks to advances in immunology and oncology, pharmaceuticals and devices are now at the forefront. Investors have been reassured by the separation that J&J’s future is driven by science and Kenvue’s is driven by consumers. Although they have very distinct mandates, both still belong to the same cultural fabric.
